GlassScriptPhysician profile
Charles M Bolno
NPI 1427113349
$12,636.53
in general payments reported to CMS, 2019-2025
53 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,362 · 2020: $1,309 · 2021: $2,254 · 2022: $2,649 · 2023: $2,931 · 2024: $2,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,063.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,580.36 | 2021-2024 | Qulipta, Ubrelvy, Vraylar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,548.60 | 2019-2024 | Xifaxan, Trulance, Relistor |
| Astrazeneca Pharmaceuticals LP | $1,353.32 | 2019-2023 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $954.38 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $934.65 | 2019-2024 | |
| Lilly USA, LLC | $919.27 | 2019-2024 | Mounjaro, Trulicity |
| Novo Nordisk INC | $715.26 | 2019-2024 | Ozempic, Rybelsus |
| Abbott Laboratories | $467.09 | 2021-2024 | Proclaim, Freestyle Libre 3 |
| Horizon Therapeutics Plc | $442.26 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $415.70 | 2019-2024 | Belsomra, Dificid, Steglatro |
| Allergan, INC. | $318.60 | 2019-2020 | |
| Mylan Specialty L.P. | $279.25 | 2019-2023 | Yupelri |
| Novartis Pharmaceuticals Corporation | $242.87 | 2019-2023 | |
| Scilex Pharmaceuticals INC. | $169.82 | 2020-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $169.46 | 2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Bolno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.